Literature DB >> 32980961

Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.

Guojin Zhang1,2,3, Junlin Zhou4,5, Yuntai Cao1,2,3, Jing Zhang1,2, Zhiyong Zhao1,2, Wenjuan Zhang1,2.   

Abstract

OBJECTIVE: To analyze the relationship between dual-energy spectral CT and epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma.
METHODS: The quantitative parameters of spectral CT were analyzed in 208 patients with lung adenocarcinoma. The quantitative parameters including CT40keV and CT70keV values, effective atomic number (Zeff), iodine concentration (IC), water concentration (WC), and the slope of the spectral curve (λ HU) were calculated. Statistical analysis was used to determine the clinical characteristics and quantitative parameters for the diagnosis of EGFR-mutation status. The ROC curves were used to calculate diagnostic efficiency.
RESULTS: Sex (p = 0.027) and smoking history (p = 0.019) differed significantly according to the EGFR-mutation status. Spectral CT quantitative parameters (CT40keV and CT70keV values, λ HU, Zeff and IC) differed significantly between the EGFR mutant and the EGFR wild-type groups (p < 0.05) during the arterial phase (AP) and venous phase (VP). However, WC was not statistically different between the two groups (p > 0.05). ROC curve analysis revealed the combination of the significantly different quantitative parameters provided the best diagnostic performance for determining the EGFR-mutation status (AUC: 76.0%) in the AP, while the AUC during the VP was 75.6%.
CONCLUSION: The quantitative parameters of dual-energy spectral CT have potential value for identifying the EGFR-mutation status.

Entities:  

Keywords:  Epidermal growth factor receptor; Lung adenocarcinoma; Spectral computed tomography

Mesh:

Substances:

Year:  2020        PMID: 32980961     DOI: 10.1007/s00432-020-03402-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.

Authors:  Jae Hyun Jeon; Chang Hyun Kang; Hye-seon Kim; Yong Won Seong; In Kyu Park; Young Tae Kim
Journal:  Eur J Cardiothorac Surg       Date:  2014-04-22       Impact factor: 4.191

2.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

Authors:  C J Bruns; C C Solorzano; M T Harbison; S Ozawa; R Tsan; D Fan; J Abbruzzese; P Traxler; E Buchdunger; R Radinsky; I J Fidler
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

3.  Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling.

Authors:  Tian-Ying Jia; Jun-Feng Xiong; Xiao-Yang Li; Wen Yu; Zhi-Yong Xu; Xu-Wei Cai; Jing-Chen Ma; Ya-Cheng Ren; Rasmus Larsson; Jie Zhang; Jun Zhao; Xiao-Long Fu
Journal:  Eur Radiol       Date:  2019-02-18       Impact factor: 5.315

Review 4.  Overview of current systemic management of EGFR-mutant NSCLC.

Authors:  W-H Hsu; J C-H Yang; T S Mok; H H Loong
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

5.  Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.

Authors:  Su Jin Hong; Tae Jung Kim; Yo Won Choi; Jeong-Soo Park; Jin-Haeng Chung; Kyung Won Lee
Journal:  Eur Radiol       Date:  2016-01-19       Impact factor: 5.315

6.  Differentiation of benign and malignant lung lesions: Dual-Energy Computed Tomography findings.

Authors:  Víctor González-Pérez; Estanislao Arana; María Barrios; Albert Bartrés; Julia Cruz; Rafael Montero; Manuel González; Carlos Deltoro; Encarnación Martínez-Pérez; Karol De Aguiar-Quevedo; Miguel Arrarás
Journal:  Eur J Radiol       Date:  2016-07-28       Impact factor: 3.528

Review 7.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

8.  Clinical utility of dual-energy CT in the evaluation of solitary pulmonary nodules: initial experience.

Authors:  Eun Jin Chae; Jae-Woo Song; Joon Beom Seo; Bernhard Krauss; Yu Mi Jang; Koun-Sik Song
Journal:  Radiology       Date:  2008-09-16       Impact factor: 11.105

9.  Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy.

Authors:  Chang-Min Choi; Mi Young Kim; Jae Cheol Lee; Hwa Jung Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

10.  Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

Authors:  S Dearden; J Stevens; Y-L Wu; D Blowers
Journal:  Ann Oncol       Date:  2013-05-30       Impact factor: 32.976

View more
  3 in total

1.  Comparison of Spectral and Perfusion Computed Tomography Imaging in the Differential Diagnosis of Peripheral Lung Cancer and Focal Organizing Pneumonia.

Authors:  Liangna Deng; Guojin Zhang; Xiaoqiang Lin; Tao Han; Bin Zhang; Mengyuan Jing; Junlin Zhou
Journal:  Front Oncol       Date:  2021-10-27       Impact factor: 6.244

2.  Prediction of VEGF and EGFR Expression in Peripheral Lung Cancer Based on the Radiomics Model of Spectral CT Enhanced Images.

Authors:  Linhua Wu; Jian Li; Xiaowei Ruan; Jialiang Ren; Xuejun Ping; Bing Chen
Journal:  Int J Gen Med       Date:  2022-08-22

3.  Study on the correlation between energy spectrum computed tomography imaging and the pathological characteristics and prognosis of cervical cancer.

Authors:  Libo Pan; Xia Jia; Xuewu Zhao; Bei Zhang; Shusheng Wang; Tao Fan; Min Zhou; Yuan Yuan; Guoqing Wang; Longmei Xue
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.